References
- Bartl R, Frisch B, Von Tresckow E, Bartl C. Biphosphonates in medical practice. Heidelberg, German: Spriger-Verlag; 2007:35–70
- Rolf WS, Jan den H. Chromatographic analysis of bisphosphonates. Pharm World Sci 1999;21:1–21
- Chaiamnuay S, Saag KG. Postmenopausal osteoporosis. Rev Endocr Metab Dis 2006;7:101–2
- Porras AG, Holland SD, Gertz BJ. Pharmacokinetics of alendronate. Clin Pharmacokinet 1999;36:315–28
- Gertz BJ, Holland SD, Kline WF, et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995;58:228–98
- Kos M, Luczak K. Bisphosphonates promote jaw osteonecrosis through facilitating bacterial colonization. Biosci Hypotheses 2009;2:34
- Bone HG, Hosking D, Devogelaer JP, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189–99
- Marvola T, Marvola J, Kanerva H, et al. Neutron activation based gamma scintigraphic evaluation of enteric-coated capsules for local treatment in colon. Int J Pharm 2008;349:24–9
- Dilworth JR, Parrott SJ. The biomedical chemistry of technetium. Chem Soc Rev 1998;27:43–55
- Jurisson SS, Lydon JD. Potential technetium small molecule radiopharmaceuticals. Chem Rev 1999;99:2205–18
- Pauwels EK, Stokkel MP. Radiopharmaceuticals for bone lesions. Imaging and therapy in clinical practice. Q J Nucl Med 2001;45:18–26
- Mendez-Rojas MA, Kharisov BI, Tsivadze AY. Recent advances on technetium complexes: coordination chemistry and medical applications. J Coord Chem 2006;59:1–63
- Bartholom MD, Louie AS, Valliant JF, Zubieta J. Technetium and gallium derived radiopharmaceuticals: comparing and contrasting the chemistry of two important radiometals for the molecular imaging era. Chem Rev 2010;110:2903–20
- El-Mabhout AA, Mercer JR. 188Re-labeled bisphosphonates as potential bifunctional agents for therapy in patients with bone metastases. Appl Radiat Isot 2005;62:541–9
- Mari C, Catafau A, Carrio I. Bone scintigraphy and metabolic disorders. Q J Nucl Med 1999;43:259–67
- Palma E, Oliveira BL, Correia JD, et al. A new bisphosphonate-containing 99 mTc(I) tricarbonyl complex potentially useful as bone-seeking agent: synthesis and biological evaluation. J Biol Inorg Chem 2007;12:667–79
- Shigematsu M, Shiomi S, Iwao H, Ochi H. New bone-seeking agent: animal study of Tc-99m-incadronate. Ann Nucl Med 2002;16:55–9
- Schampt K, Schreder SA, Dressman J. Development of an/in vitro/in vivo correlation for lipid formulations of EMD 50733, a poorly soluble, lipophilic drug substance. Eur J Pharm Biopharm 2006;62:227–34
- Kovarik JM, Mueller EA, Van Bree JB, et al. Reduced inter-and intra individual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 1994;83:444–7
- Chae GS, Lee JS, Kim SH, et al. Enhancement of the stability of BCNU using self-emulsifying drug delivery systems (SEEDS) and in vitro antitumor activity of self-emulsified BCNU-loaded PLGA wafer. Int J Pharm 2005;301:6–14
- Sousa JJ, Sousa A, Moura MJ, et al. The influence of core materials and film coating on the drug release from coated pellets. Int J Pharm 2002;233:11–122
- Constantinides PP, Yiv SH. Particle size determination of phase-inverted water-in-oil microemulsions under different dilution and storage conditions. Int J Pharm 1995;115:225–34
- Shah NH, Carvajal MT, Patel CI, et al. Self-emulsifying drug delivery systems (SEEDS) with polyglycolysed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int J Pharm 1994;106:15–23
- Charman SA, Charman WN, Rogge MC, et al. Self-emulsifying drug delivery systems: formulation and biopharmaceutical evaluation of an investigational lipophilic compound. Pharm Res 1992;9:87–93
- Parmar N, Singla N, Amin S, Kohli K. Study of cosurfactant effect on nanoemulsifying area and development of lercanidipine loaded self nanoemulsifying drug delivery system. Colloids Surf B 2011;86:327–38
- Wu W, Wang Y, Que L. Enhanced bioavailability of silymarin by self microemulsifying drug delivery systems. Eur J Biopharm 2006;63:288–94
- Çelik N. Radiolabeling of risedronate sodium with 99mTc for bone imaging [master thesis]. İzmir: Ege University Radiopharmacy Department; 2012
- Ghassabian S, Wright AL, Dejager AD, Smith MT. Development and validation of sensitive solid phase extraction (SPE) method using high performance liquid chromatography/tandem mass spectrometry for determination of risedronate concentrations in human plasma. J Chromatogr B 2012;881–882:34–41
- Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 2001;46:27–43
- Kogan A, Kesselman E, Danino D, et al. Viability and permeability across Caco-2 cells of carbamazepine solubilized in fully dilutable microemulsions. Colloids Surf B 2008;66:1–12
- Yee S. In vivo permeability across Caco-2 cells can predict in vivo (small intestine) in man-fact or myth. Pharm Res 1997;14:763–6
- Wu W, Wang Y, Que L. Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system. Eur J Pharm Biopharm 2006;63:288–94
- Yang S, Gursoy RN, Lambert G, Benita S. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm Res 2004;21:261–70
- Swenson ES, Curatolo WJ. Means to enhance penetration. Adv Drug Deliv Rev 1992;8:39–42
- Konsoula R, Barile FA. Correlation of in vitro cytotoxicity with paracellular permeability in Caco-2 cells. Toxicol In Vitro 2005;19:675–84
- Maestrelli F, Zerrouk N, Chemtob C, Mura P. Influence of chitosan and its glutamate and hydrochloride salts on naproxen dissolution rate and permeation across Caco-2 cells. Int J Pharm 2004;271:257–67